1. A patient receives high pharmacological doses of a glucocorticoid that, unlike dexamethasone, is a good substrate for the renal enzyme 11beta-HSD2 (11-beta-hydroxysteroid dehydrogenase type 2), which normally inactivates cortisol in the distal nephron. Over time the patient develops hypertension, edema, and hypokalemia. Which mechanism best integrates these findings?
A) The glucocorticoid directly antagonizes the mineralocorticoid receptor (MR), causing renal sodium wasting and reflex potassium loss
B) The glucocorticoid stimulates renin release, raising angiotensin II and causing potassium loss without sodium retention
C) At high concentrations the steroid load saturates 11beta-HSD2, so cortisol escapes inactivation and activates renal MR, driving sodium and water retention with potassium secretion
D) The glucocorticoid blocks aldosterone synthase, lowering aldosterone and producing compensatory hypertension
E) The glucocorticoid inhibits the epithelial sodium channel (ENaC), producing paradoxical volume expansion
ANSWER: C
Rationale:
Option C is correct. Renal MR is normally shielded from cortisol by 11beta-HSD2, which converts cortisol to inactive cortisone. A high pharmacological load of a cortisol-like glucocorticoid saturates this enzyme; cortisol then escapes inactivation, activates renal MR, and drives ENaC-mediated sodium reabsorption with water retention and potassium secretion, producing hypertension, edema, and hypokalemia. Dexamethasone, a poor 11beta-HSD2 substrate and weak MR agonist, does not reproduce this pattern, which is why the question specifies a cortisol-like steroid.
Option A: Option A is incorrect because the steroid activates rather than antagonizes MR; MR antagonism would cause sodium loss and potassium retention, the opposite of the findings.
Option B: Option B is incorrect because the picture is mineralocorticoid-like sodium retention with volume expansion, which suppresses renin rather than depending on its stimulation.
Option D: Option D is incorrect because the syndrome results from cortisol activating MR, not from aldosterone-synthase blockade; lowering aldosterone would not cause sodium retention and hypokalemia by this route.
Option E: Option E is incorrect because MR activation increases ENaC activity; inhibiting ENaC would cause sodium loss, not volume expansion.
2. A man with heart failure with reduced ejection fraction develops painful gynecomastia on spironolactone, and the team switches to eplerenone for continued mineralocorticoid receptor (MR) blockade. Which statement best integrates the rationale and the practical tradeoff of this switch?
A) Eplerenone avoids gynecomastia because it is selective for MR without androgen-receptor antagonism, but its lower MR potency means twice-daily dosing and higher cost are generally required
B) Eplerenone avoids gynecomastia because it is a non-steroidal agent, and it is more potent than spironolactone so doses can be reduced
C) Eplerenone avoids gynecomastia because it blocks the androgen receptor more completely, normalizing breast tissue
D) Eplerenone avoids gynecomastia because it is an MR agonist rather than antagonist, sparing breast tissue
E) Eplerenone avoids gynecomastia because it is converted to canrenone, an inactive metabolite with no endocrine effect
ANSWER: A
Rationale:
Option A is correct. Gynecomastia from spironolactone arises from androgen-receptor antagonism. Eplerenone is a selective steroidal MR antagonist with negligible androgen-, progesterone-, and glucocorticoid-receptor affinity, so it preserves MR blockade without the endocrine effects. The tradeoff is that eplerenone is roughly 60-fold less potent at MR, so it is dosed twice daily and costs more.
Option B: Option B is incorrect because eplerenone is steroidal (finerenone is the non-steroidal antagonist) and is less, not more, potent than spironolactone.
Option C: Option C is incorrect because eplerenone avoids gynecomastia by not antagonizing the androgen receptor; it does not block it more completely.
Option D: Option D is incorrect because eplerenone is an MR antagonist, not an agonist.
Option E: Option E is incorrect because canrenone is the active metabolite of spironolactone, not a feature of eplerenone, and it is not inactive.
3. A patient with an estimated glomerular filtration rate (eGFR) of 38 mL per minute per 1.73 m2 is already taking an angiotensin-converting enzyme (ACE) inhibitor when a mineralocorticoid receptor (MR) antagonist is added. Integrating these factors, which adverse outcome is most likely, and what monitoring is most important?
A) Hypokalemia; monitor with periodic potassium because MR antagonists waste potassium
B) Hyponatremia; monitor sodium because MR antagonists cause salt retention
C) Hypoglycemia; monitor glucose because MR antagonists suppress insulin
D) Hyperkalemia; monitor serum potassium closely because reduced renal function and concurrent renin-angiotensin-aldosterone system (RAAS) blockade compound the potassium-sparing effect of MR antagonism
Option D is correct. MR antagonists reduce renal potassium secretion. When combined with reduced eGFR (estimated glomerular filtration rate) and concurrent RAAS (renin-angiotensin-aldosterone system) blockade by an ACE inhibitor, the potassium-retaining effects compound, making hyperkalemia the predictable and dangerous outcome. Serum potassium is therefore the key monitoring parameter.
Option A: Option A is incorrect because MR antagonists are potassium-sparing and cause hyperkalemia, not hypokalemia.
Option B: Option B is incorrect because these agents promote natriuresis; the dose-limiting concern in this scenario is potassium, not sodium retention.
Option C: Option C is incorrect because hypoglycemia from insulin suppression is unrelated to MR antagonism; that effect belongs to pasireotide.
Option E: Option E is incorrect because MR antagonists do not characteristically cause hypercalcemia.
4. Two patients both require glucocorticoid replacement: Patient 1 has autoimmune destruction of the adrenal cortex, and Patient 2 has panhypopituitarism after pituitary surgery. Applying the pharmacological basis for mineralocorticoid replacement, which patient also needs fludrocortisone, and why?
A) Patient 2 only, because pituitary failure removes the renin-angiotensin-aldosterone drive to the adrenal cortex
B) Patient 1 only, because adrenal cortical destruction abolishes aldosterone production, whereas Patient 2 retains a renin-responsive zona glomerulosa
C) Both patients, because any cause of cortisol deficiency equally impairs aldosterone synthesis
D) Neither patient, because glucocorticoid replacement restores aldosterone secretion in both
E) Patient 2 only, because hypopituitarism causes hyperkalemia that requires fludrocortisone
ANSWER: B
Rationale:
Option B is correct. Patient 1 has primary adrenal insufficiency: destruction of the cortex eliminates aldosterone production, so fludrocortisone is required. Patient 2 has secondary adrenal insufficiency from pituitary failure; the zona glomerulosa is intact and remains responsive to the renin-angiotensin-aldosterone system, so aldosterone is preserved and mineralocorticoid replacement is unnecessary.
Option A: Option A is incorrect because aldosterone is driven principally by the renin-angiotensin-aldosterone system and potassium, not by pituitary ACTH; pituitary failure does not remove that drive.
Option C: Option C is incorrect because cortisol and aldosterone synthesis are not equally impaired by every cause; secondary insufficiency spares aldosterone.
Option D: Option D is incorrect because glucocorticoid replacement does not restore aldosterone; in primary insufficiency a mineralocorticoid is still required.
Option E: Option E is incorrect because hyperkalemia is a feature of primary, not secondary, insufficiency, and hypopituitarism does not by itself create a fludrocortisone requirement.
5. A patient on high-dose metyrapone for severe Cushing syndrome develops worsening hypertension and hypokalemia along with new acne and hirsutism. Integrating metyrapone's mechanism with the consequences of precursor shunting, which explanation accounts for both problems?
A) Metyrapone directly stimulates aldosterone synthase, raising aldosterone and androgens simultaneously
B) Metyrapone inhibits CYP3A4, raising levels of an unrelated mineralocorticoid drug while causing androgen excess
C) Metyrapone blocks the androgen receptor, paradoxically increasing hair growth, and retains sodium independently
D) Metyrapone causes adrenal insufficiency, and the hypertension and hirsutism are unrelated rebound effects
E) By blocking CYP11B1, metyrapone shunts ACTH-driven precursors into deoxycorticosterone (a mineralocorticoid causing sodium retention, hypertension, and hypokalemia) and into the adrenal androgen pathway (causing acne and hirsutism)
ANSWER: E
Rationale:
Option E is correct. Metyrapone inhibits CYP11B1, the final step of cortisol synthesis. With cortisol synthesis blocked and ACTH (adrenocorticotropic hormone) drive persisting, precursors accumulate and are shunted: into deoxycorticosterone, a mineralocorticoid that causes sodium retention, hypertension, and hypokalemia, and into the adrenal androgen pathway, producing acne and hirsutism. A single mechanism, precursor shunting upstream of the block, explains both problems.
Option A: Option A is incorrect because metyrapone does not stimulate aldosterone synthase; the mineralocorticoid effect comes from deoxycorticosterone accumulation, not increased aldosterone.
Option B: Option B is incorrect because the effects arise from metyrapone's own precursor shunting, not from CYP3A4-mediated interaction with another drug.
Option C: Option C is incorrect because metyrapone does not block the androgen receptor; it increases androgen precursors, and the sodium retention is from deoxycorticosterone, not an independent action.
Option D: Option D is incorrect because the hypertension and hirsutism are directly explained by precursor shunting, not unrelated rebound phenomena.
6. A patient with Cushing syndrome and diabetes is treated with mifepristone. The team notes that urinary free cortisol (UFC) is rising and the patient develops hypokalemia. Integrating mifepristone's mechanism, which explanation accounts for both observations?
A) Mifepristone inhibits cortisol synthesis, so falling cortisol triggers compensatory potassium loss and lowers UFC
B) Mifepristone blocks the mineralocorticoid receptor, raising potassium excretion and reducing measurable cortisol
C) By antagonizing the glucocorticoid receptor (GR), mifepristone removes cortisol feedback (so cortisol and UFC rise, making UFC uninformative) while the elevated cortisol activates unopposed mineralocorticoid receptors, producing hypokalemia
D) Mifepristone destroys adrenal tissue, so UFC rises transiently and potassium falls from cell lysis
E) Mifepristone induces CYP3A4, accelerating cortisol metabolism and causing both findings
ANSWER: C
Rationale:
Option C is correct. Mifepristone is a glucocorticoid-receptor (GR) antagonist. Blocking GR removes negative feedback, so ACTH (adrenocorticotropic hormone), plasma cortisol, and UFC (urinary free cortisol) rise, which is why UFC cannot be used to monitor response. The elevated cortisol is not opposed at the mineralocorticoid receptor (because GR, not MR, is blocked), so cortisol activates MR and produces hypokalemia. One mechanism, GR blockade with consequent cortisol elevation, explains both the rising UFC and the hypokalemia.
Option A: Option A is incorrect because mifepristone does not inhibit cortisol synthesis; cortisol and UFC rise rather than fall.
Option B: Option B is incorrect because mifepristone blocks GR, not MR; the hypokalemia results from cortisol acting at unopposed MR, and UFC actually increases.
Option D: Option D is incorrect because mifepristone acts at the receptor and does not destroy adrenal tissue.
Option E: Option E is incorrect because mifepristone's effect here is receptor antagonism, not CYP3A4 induction; accelerated metabolism would not raise UFC.
7. In congenital adrenal hyperplasia (CAH), clinicians must balance suppression of the early-morning rise in adrenal androgen precursors against the growth-impairing effects of glucocorticoid excess. Integrating these competing goals, which statement about agent and dosing choice is correct?
A) In growing children, divided-dose hydrocortisone is preferred because its short half-life limits suppression of nocturnal growth hormone and bone growth, whereas bedtime dexamethasone, though effective at suppressing the nocturnal ACTH surge, carries greater risk of growth impairment and metabolic effects
B) In growing children, bedtime dexamethasone is preferred because its long half-life maximizes linear growth
C) In growing children, once-daily morning hydrocortisone is preferred because a single dose best suppresses the nocturnal precursor rise
D) In all CAH patients, the goal is full normalization of 17-hydroxyprogesterone regardless of glucocorticoid dose
E) In growing children, fludrocortisone alone suppresses ACTH and controls androgens without glucocorticoid
ANSWER: A
Rationale:
Option A is correct. In children the priority is to protect linear growth, so divided-dose hydrocortisone is favored: its short half-life suppresses ACTH (adrenocorticotropic hormone)-driven precursors while minimizing suppression of the nocturnal growth hormone surge and bone growth. Long-acting bedtime dexamethasone strongly suppresses the nocturnal ACTH rise but carries a higher risk of growth impairment and metabolic adverse effects, so it is reserved rather than first-line in children.
Option B: Option B is incorrect because dexamethasone's long half-life increases the risk of growth impairment; it does not maximize growth.
Option C: Option C is incorrect because once-daily hydrocortisone leaves prolonged gaps of inadequate suppression; divided dosing is required for steady control.
Option D: Option D is incorrect because complete normalization of 17-hydroxyprogesterone typically requires glucocorticoid excess; guidelines accept mild elevation to protect growth.
Option E: Option E is incorrect because fludrocortisone is a mineralocorticoid and does not provide the glucocorticoid-mediated ACTH suppression needed to control androgens.
8. A patient with Cushing disease is started on pasireotide and the urinary free cortisol improves, but fasting glucose climbs markedly within weeks. Integrating the drug's receptor pharmacology, which statement best explains this and guides management?
A) The hyperglycemia reflects worsening hypercortisolism, so the pasireotide dose should be increased
B) The hyperglycemia is an allergic reaction unrelated to mechanism and warrants drug discontinuation
C) Pasireotide blocks the glucocorticoid receptor, and rising cortisol causes the hyperglycemia
D) Pasireotide activates somatostatin receptors not only on corticotrophs (lowering ACTH) but also on pancreatic islets, suppressing insulin and incretin secretion, so glucose must be monitored and antidiabetic therapy often initiated
E) Pasireotide induces CYP3A4, lowering levels of the patient's oral antidiabetic drug and causing hyperglycemia
ANSWER: D
Rationale:
Option D is correct. Pasireotide is a somatostatin analog that activates somatostatin receptor subtype 5 on corticotroph adenoma cells to lower ACTH (adrenocorticotropic hormone) and cortisol. The same somatostatin-receptor activation on pancreatic islets suppresses insulin and incretin secretion, producing hyperglycemia in roughly 70% of patients. Management is to monitor glucose and frequently start antidiabetic therapy rather than abandon an otherwise effective drug.
Option A: Option A is incorrect because the cortisol response is improving; the hyperglycemia is a direct islet effect, not a sign of worsening hypercortisolism, and raising the dose would worsen it.
Option B: Option B is incorrect because the hyperglycemia is a predictable mechanistic effect, not an allergic reaction.
Option C: Option C is incorrect because glucocorticoid-receptor blockade describes mifepristone; pasireotide acts through somatostatin receptors, and cortisol is falling here.
Option E: Option E is incorrect because the hyperglycemia is caused by direct islet suppression of insulin and incretin, not by a CYP3A4 interaction.
9. A patient with adrenocortical carcinoma on mitotane needs more glucocorticoid than a typical replacement dose, and the team also notices that another medication metabolized by CYP3A4 (cytochrome P450 3A4) is becoming subtherapeutic. Integrating mitotane's pharmacology, which mechanism explains both observations?
A) Mitotane inhibits CYP3A4 and lowers corticosteroid-binding globulin, raising free drug and free cortisol
B) Mitotane increases corticosteroid-binding globulin (lowering free cortisol) and induces CYP3A4 (accelerating metabolism of glucocorticoids and other CYP3A4 substrates), so higher glucocorticoid doses are needed and co-administered CYP3A4 substrates fall
C) Mitotane antagonizes the glucocorticoid receptor, so more glucocorticoid is needed, and it has no effect on other drugs
D) Mitotane blocks renal excretion of glucocorticoids, raising their levels, while inhibiting metabolism of other drugs
E) Mitotane stimulates cortisol synthesis, so replacement needs fall, and it slows metabolism of other agents
ANSWER: B
Rationale:
Option B is correct. Mitotane increases corticosteroid-binding globulin, which lowers the free cortisol fraction, and it induces CYP3A4 (cytochrome P450 3A4), which accelerates metabolism of glucocorticoids. Both effects raise the glucocorticoid dose needed for adequate free-hormone exposure. The same CYP3A4 induction accelerates metabolism of other CYP3A4 substrates, driving them toward subtherapeutic levels. A single induction-plus-binding mechanism explains both observations.
Option A: Option A is incorrect because mitotane induces, not inhibits, CYP3A4, and it raises rather than lowers corticosteroid-binding globulin.
Option C: Option C is incorrect because mitotane does not antagonize the glucocorticoid receptor, and it clearly does affect other CYP3A4 substrates.
Option D: Option D is incorrect because the dominant mechanism is increased binding protein and enzyme induction, not blocked renal excretion or inhibited metabolism.
Option E: Option E is incorrect because mitotane is adrenocorticolytic and lowers cortisol, increasing replacement needs, and it induces rather than slows metabolism.
10. A patient with known primary adrenal insufficiency presents in adrenal crisis with hypotension refractory to fluids, hyponatremia, hyperkalemia, and hypoglycemia. Integrating the combined hormone deficiencies that drive this picture, which management approach is mechanistically correct?
A) Give fludrocortisone alone, because the electrolyte derangements are purely mineralocorticoid in origin
B) Give intravenous insulin and potassium-lowering therapy first, deferring steroids until electrolytes normalize
C) Give oral hydrocortisone and recheck electrolytes in the morning
D) Give dexamethasone only, because mineralocorticoid effects are not relevant in crisis
E) Give immediate intravenous hydrocortisone plus aggressive normal saline, because the hyponatremia, hyperkalemia, and hypotension reflect mineralocorticoid deficiency while the hypoglycemia and poor vascular tone reflect glucocorticoid deficiency, both corrected by stress-dose hydrocortisone and volume
ANSWER: E
Rationale:
Option E is correct. In primary adrenal crisis the findings integrate two deficiencies: mineralocorticoid deficiency produces sodium and volume loss with hyponatremia, hyperkalemia, and hypotension, while glucocorticoid deficiency impairs gluconeogenesis (hypoglycemia) and vascular responsiveness. Immediate intravenous hydrocortisone at stress doses supplies glucocorticoid effect and, at those doses, sufficient mineralocorticoid activity, and aggressive normal saline restores sodium and volume. Treatment must not be delayed for laboratory results.
Option A: Option A is incorrect because fludrocortisone alone is oral, slow, and does not address the glucocorticoid deficiency or provide volume resuscitation needed in crisis.
Option B: Option B is incorrect because withholding steroids to first correct electrolytes is dangerous; glucocorticoid and volume replacement are the definitive treatment and themselves correct the derangements.
Option C: Option C is incorrect because a hypotensive, ill patient cannot rely on oral absorption, and delaying reassessment risks death.
Option D: Option D is incorrect because, although hydrocortisone is the agent of choice partly for its mineralocorticoid effect, dexamethasone lacks meaningful mineralocorticoid activity and would not address the sodium and volume deficit; the framing that mineralocorticoid effects are irrelevant is wrong.
11. A patient taking ketoconazole to control hypercortisolism is also prescribed a drug that is extensively metabolized by CYP3A4 (cytochrome P450 3A4) and has a narrow therapeutic window. Integrating ketoconazole's pharmacology beyond its steroidogenesis effects, what is the most likely consequence?
A) The co-administered drug's plasma levels fall, risking treatment failure, because ketoconazole induces CYP3A4
B) No interaction occurs, because ketoconazole acts only on adrenal enzymes
C) The co-administered drug's plasma levels rise, risking toxicity, because ketoconazole is a potent inhibitor of CYP3A4
D) The co-administered drug is unaffected, but ketoconazole levels fall
E) Both drugs are eliminated faster because ketoconazole accelerates renal clearance
ANSWER: C
Rationale:
Option C is correct. Beyond inhibiting adrenal steroidogenic enzymes, ketoconazole is a potent inhibitor of CYP3A4 (cytochrome P450 3A4). Co-administering a narrow-therapeutic-window drug that depends on CYP3A4 for clearance leads to reduced metabolism, rising plasma concentrations, and risk of toxicity, a clinically important and predictable interaction.
Option A: Option A is incorrect because ketoconazole inhibits, rather than induces, CYP3A4; levels of the substrate rise, not fall.
Option B: Option B is incorrect because ketoconazole's potent CYP3A4 inhibition produces systemic drug interactions well beyond the adrenal gland.
Option D: Option D is incorrect because the affected drug is the CYP3A4 substrate, whose levels rise; the interaction is not limited to ketoconazole's own levels.
Option E: Option E is incorrect because ketoconazole inhibits hepatic metabolism rather than accelerating renal clearance.
12. A patient with type 2 diabetes and diabetic kidney disease on maximally tolerated renin-angiotensin-aldosterone system (RAAS) blockade is started on finerenone, and the benefit is attributed to effects beyond blood-pressure lowering and diuresis. Integrating mineralocorticoid receptor (MR) biology with finerenone's properties, which explanation is correct?
A) Finerenone works only by enhancing urinary sodium loss, identical to a thiazide diuretic
B) Finerenone blocks MR in non-epithelial tissues such as the heart and kidney, where MR activation drives fibrosis, inflammation, and podocyte injury, and its balanced cardiac-renal distribution targets these processes to reduce cardiorenal events independently of blood pressure
C) Finerenone acts as an MR agonist in the kidney, increasing aldosterone-mediated protection
D) Finerenone lowers cardiorenal risk by inhibiting angiotensin-converting enzyme, adding to RAAS blockade
Option B is correct. MR is expressed in non-epithelial tissues, including cardiac fibroblasts and myocytes, vascular cells, and renal podocytes and mesangial cells, where its activation promotes fibrosis, inflammation, and proteinuria independent of sodium handling. Finerenone is a non-steroidal MR antagonist with balanced distribution between heart and kidney, so it targets these remodeling processes and reduces cardiorenal events beyond its blood-pressure and diuretic effects.
Option A: Option A is incorrect because the added benefit is precisely the non-epithelial anti-remodeling effect, not a thiazide-like diuretic action.
Option C: Option C is incorrect because finerenone antagonizes MR; it is not an agonist.
Option D: Option D is incorrect because finerenone does not inhibit angiotensin-converting enzyme; it blocks MR.
Option E: Option E is incorrect because finerenone tends to raise, not lower, serum potassium, and its benefit is anti-fibrotic, not from potassium reduction.
13. A patient with primary adrenal insufficiency on fludrocortisone returns with new hypertension, lower-extremity edema, mild hypokalemia, and a suppressed plasma renin activity. Integrating these monitoring parameters, which interpretation and action is correct?
A) These findings indicate fludrocortisone over-replacement; the dose should be reduced, since excess mineralocorticoid effect causes sodium retention, hypertension, edema, hypokalemia, and suppressed renin
B) These findings indicate under-replacement; the dose should be increased to raise blood pressure
C) These findings indicate glucocorticoid deficiency; hydrocortisone should be increased
D) These findings indicate an adrenal crisis; emergency intravenous saline and steroids are required
E) These findings indicate appropriate replacement; no change is needed despite the suppressed renin
ANSWER: A
Rationale:
Option A is correct. Fludrocortisone is titrated to a mid-normal plasma renin activity with normal electrolytes, normal blood pressure, and no edema. Hypertension, edema, hypokalemia, and a suppressed renin together indicate excessive mineralocorticoid effect, that is, over-replacement, and the correct action is to reduce the fludrocortisone dose.
Option B: Option B is incorrect because under-replacement causes the opposite pattern, sodium wasting with hyperkalemia, postural hypotension, and elevated renin; increasing the dose would worsen this patient.
Option C: Option C is incorrect because the findings are mineralocorticoid excess, not glucocorticoid deficiency, which would not cause hypertension with suppressed renin.
Option D: Option D is incorrect because the picture is over-replacement, the opposite of crisis; the patient is hypertensive, not hypotensive.
Option E: Option E is incorrect because the suppressed renin with hypertension and hypokalemia signals over-replacement that warrants dose reduction, not continuation.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.